Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Löck, Steffen [VerfasserIn]   i
 Linge, Annett [VerfasserIn]   i
 Lohaus, Fabian [VerfasserIn]   i
 Ebert, Nadja [VerfasserIn]   i
 Gudziol, Volker [VerfasserIn]   i
 Nowak, Alexander [VerfasserIn]   i
 Tinhofer, Ingeborg [VerfasserIn]   i
 Kalinauskaite, Goda [VerfasserIn]   i
 Guberina, Maja [VerfasserIn]   i
 Stuschke, Martin [VerfasserIn]   i
 Balermpas, Panagiotis [VerfasserIn]   i
 von der Grün, Jens [VerfasserIn]   i
 Grosu, Anca-Ligia [VerfasserIn]   i
 Debus, Jürgen [VerfasserIn]   i
 Ganswindt, Ute [VerfasserIn]   i
 Belka, Claus [VerfasserIn]   i
 Peeken, Jan C. [VerfasserIn]   i
 Combs, Stephanie E. [VerfasserIn]   i
 De-Colle, Chiara [VerfasserIn]   i
 Zips, Daniel [VerfasserIn]   i
 Baretton, Gustavo B. [VerfasserIn]   i
 Krause, Mechthild [VerfasserIn]   i
 Baumann, Michael [VerfasserIn]   i
Titel:Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC
Titelzusatz:hypothesis generation on a multicentre cohort of the DKTK-ROG
Verf.angabe:Steffen Löck, Annett Linge, Fabian Lohaus, Nadja Ebert, Volker Gudziol, Alexander Nowak, Ingeborg Tinhofer, Goda Kalinauskaite, Maja Guberina, Martin Stuschke, Panagiotis Balermpas, Jens von der Grün, Anca-Ligia Grosu, Jürgen Debus, Ute Ganswindt, Claus Belka, Jan C. Peeken, Stephanie E. Combs, Chiara De-Colle, Daniel Zips, Gustavo B. Baretton, Mechthild Krause, Michael Baumann, for the DKTK-ROG
E-Jahr:2022
Jahr:16 February 2022
Umfang:7 S.
Fussnoten:Gesehen am 31.05.2022
Titel Quelle:Enthalten in: Radiotherapy and oncology
Ort Quelle:Amsterdam [u.a.] : Elsevier Science, 1983
Jahr Quelle:2022
Band/Heft Quelle:169(2022) vom: Apr., Seite 8-14
ISSN Quelle:1879-0887
Abstract:Purpose - To develop prognostic biomarker signatures for patients with locally advanced head and neck squamous cell carcinoma (HNSCC) treated by primary radiochemotherapy (RCTx) based on previously published molecular analyses of the retrospective biomarker study of the German Cancer Consortium - Radiation Oncology Group (DKTK-ROG). - Material and methods - In previous studies on the retrospective DKTK-ROG HNSCC cohort treated with primary RCTx, the following clinical parameters and biomarkers were evaluated and found to be significantly associated with loco-regional tumour control (LRC) or overall survival (OS): tumour volume, p16 status, expression of cancer stem cell markers CD44 and SLC3A2, expressions of hypoxia-associated gene signatures, tumour mutational burden (TMB), single nucleotide polymorphisms (SNPs) in the ERCC2 gene (rs1799793, rs13181) and ERCC5 gene (rs17655) as well as the expression of CXCR4, SDF-1 and CD8. These biomarkers were combined in multivariable modelling using Cox-regression with backward variable selection. - Results - A baseline signature containing the widely accepted parameters tumour volume, p16 status, cancer stem cell marker expression (CD44), and hypoxia-associated gene expression has been defined, representing the main hypothesis of the study. Furthermore, the baseline signature was extended by additional prognostic biomarkers and a data-driven signature without any pre-hypothesis was generated for both endpoints. In these signatures, the SNPs rs1799793 and rs17655 as well as CXCR4, SDF-1 and SLC3A2 expression were additionally included. The signatures showed significant patient stratifications for LRC and OS. - Conclusion - Three biomarker signatures were defined for patients with locally advanced HNSCC treated with primary RCTx for the endpoints LRC and OS. These signatures will be validated in the prospective HNprädBio study of the DKTK-ROG that recently completed recruitment, before potential application in an interventional trial.
DOI:doi:10.1016/j.radonc.2022.02.009
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext ; Verlag: https://doi.org/10.1016/j.radonc.2022.02.009
 Volltext: https://www.sciencedirect.com/science/article/pii/S0167814022000949
 DOI: https://doi.org/10.1016/j.radonc.2022.02.009
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Biomarkers
 HNSCC
 Primary radiochemotherapy
 Signature
 Validation
K10plus-PPN:1805321307
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68924160   QR-Code
zum Seitenanfang